0 10 Inhibition Inhibition NNP 11 13 of of IN 14 22 NF-kappa NF-kappa NNP 23 24 B B NNP 25 35 activation activation NN 36 38 in in IN 39 44 human human JJ 45 51 T-cell t-cell NN 52 57 lines line NNS 58 60 by by IN 61 81 anetholdithiolthione anetholdithiolthione NN 81 82 . . . 84 91 Nuclear nuclear JJ 92 98 factor factor NN 99 100 ( ( ( 100 109 NF)-kappa NF)-kappa NNP 110 111 B B NNP 112 114 is be VBZ 115 116 a a DT 117 122 redox redox NN 123 132 sensitive sensitive JJ 133 142 cytosolic cytosolic JJ 143 156 transcription transcription NN 157 163 factor factor NN 163 164 . . . 165 170 Redox Redox NNP 171 181 regulation regulation NN 182 184 of of IN 185 193 NF-kappa NF-kappa NNP 194 195 B B NNP 196 199 has have VBZ 200 204 been be VBN 205 215 implicated implicate VBN 216 218 in in IN 219 222 the the DT 223 233 activation activation NN 234 236 of of IN 237 240 the the DT 241 246 human human JJ 247 264 immuno-deficiency immuno-deficiency NN 265 270 virus virus NN 271 272 ( ( ( 272 275 HIV HIV NNP 275 276 ) ) ) 276 277 . . . 278 287 Therefore therefore RB 287 288 , , , 289 299 inhibition inhibition NN 300 302 of of IN 303 311 NF-kappa NF-kappa NNP 312 313 B B NNP 314 324 activation activation NN 325 328 may may MD 329 331 be be VB 332 334 an an DT 335 344 effective effective JJ 345 353 strategy strategy NN 354 357 for for IN 358 366 acquired acquire VBN 367 383 immunodeficiency immunodeficiency NN 384 392 syndrome syndrome NN 393 400 therapy therapy NN 400 401 . . . 402 422 Anetholdithiolthione Anetholdithiolthione NNP 423 424 ( ( ( 424 427 ADT ADT NNP 427 428 , , , 429 472 5-[p-methoxyphenyl]-3H-1,2-dithiol-3-thione 5-[p-methoxyphenyl]-3h-1,2-dithiol-3-thione NN 472 473 ) ) ) 474 476 is be VBZ 477 479 an an DT 480 491 antioxidant antioxidant NN 492 497 which which WDT 498 501 has have VBZ 502 506 been be VBN 507 511 used use VBN 512 514 to to TO 515 522 protect protect VB 523 530 against against IN 531 545 acetaminophen- acetaminophen- NN 546 549 and and CC 550 562 CCl4-induced ccl4-induced JJ 563 577 hepatotoxicity hepatotoxicity NN 577 578 , , , 579 584 lipid lipid NN 585 597 peroxidation peroxidation NN 597 598 , , , 599 608 radiation radiation NN 609 615 injury injury NN 615 616 , , , 617 620 and and CC 621 625 also also RB 626 629 has have VBZ 630 634 been be VBN 635 639 used use VBN 640 650 clinically clinically RB 651 653 as as IN 654 656 an an DT 657 672 anti-choleretic anti-choleretic JJ 673 678 agent agent NN 678 679 . . . 680 683 The the DT 684 691 present present JJ 692 697 study study NN 698 706 examined examine VBD 707 710 the the DT 711 717 effect effect NN 718 720 of of IN 721 724 ADT ADT NNP 725 737 pretreatment pretreatment NN 738 740 on on IN 741 749 NF-kappa NF-kappa NNP 750 751 B B NNP 752 762 activation activation NN 763 765 in in IN 766 774 response response NN 775 777 to to TO 778 779 a a DT 780 787 variety variety NN 788 790 of of IN 791 798 stimuli stimulus NNS 799 803 such such JJ 804 806 as as IN 807 811 H2O2 h2o2 NN 811 812 , , , 813 820 phorbol phorbol NN 821 830 myristate myristate NN 831 838 acetate acetate NN 839 840 ( ( ( 840 843 PMA PMA NNP 843 844 ) ) ) 845 847 or or CC 848 853 tumor tumor NN 854 862 necrosis necrosis NN 863 869 factor factor NN 870 875 alpha alpha NN 876 877 ( ( ( 877 880 TNF TNF NNP 881 886 alpha alpha NN 886 887 ) ) ) 887 888 . . . 889 892 PMA PMA NNP 893 896 and and CC 897 900 TNF TNF NNP 901 906 alpha alpha NN 907 914 induced induce VBD 915 925 activation activation NN 926 928 of of IN 929 930 ( ( ( 930 939 NF)-kappa NF)-kappa NNP 940 941 B B NNP 942 944 in in IN 945 950 human human JJ 951 957 Jurkat Jurkat NNP 958 965 T-cells T-cell NNP 966 969 was be VBD 970 979 partially partially RB 980 989 inhibited inhibit VBN 990 992 by by IN 993 996 ADT ADT NNP 997 998 ( ( ( 998 1001 0.1 0.1 CD 1002 1004 mM mM NNP 1004 1005 ) ) ) 1006 1019 pretreatment. pretreatment. JJ 1020 1023 ADT ADT NNP 1024 1025 ( ( ( 1025 1028 0.1 0.1 CD 1029 1031 mM mM NNP 1031 1032 ) ) ) 1033 1037 also also RB 1038 1047 inhibited inhibit VBD 1048 1052 H2O2 h2o2 NN 1053 1060 induced induced JJ 1061 1071 activation activation NN 1072 1074 of of IN 1075 1078 the the DT 1079 1092 transcription transcription NN 1093 1099 factor factor NN 1100 1102 in in IN 1103 1106 the the DT 1107 1115 peroxide peroxide NN 1116 1125 sensitive sensitive JJ 1126 1131 human human JJ 1132 1140 Wurzburg Wurzburg NNP 1141 1148 T-cells T-cell NNP 1148 1149 . . . 1150 1161 Furthermore furthermore RB 1161 1162 , , , 1163 1166 ADT ADT NNP 1167 1174 treated treat VBN 1175 1183 Wurzburg Wurzburg NNP 1184 1189 cells cell NNS 1190 1193 had have VBD 1194 1207 significantly significantly RB 1208 1214 higher high JJR 1215 1226 glutathione glutathione NN 1227 1233 levels level NNS 1234 1236 as as IN 1237 1245 compared compare VBN 1246 1250 with with IN 1251 1260 untreated untreated JJ 1261 1266 cells cell NNS 1266 1267 . . . 1268 1272 H2O2 H2O2 NNP 1273 1280 induced induce VBD 1281 1286 lipid lipid NN 1287 1299 peroxidation peroxidation NN 1300 1302 in in IN 1303 1311 Wurzburg Wurzburg NNP 1312 1317 cells cell NNS 1318 1321 was be VBD 1322 1332 remarkably remarkably RB 1333 1342 inhibited inhibit VBN 1343 1345 by by IN 1346 1349 ADT ADT NNP 1350 1362 pretreatment pretreatment NN 1362 1363 . . . 1364 1367 ADT ADT NNP 1367 1368 , , , 1369 1370 a a DT 1371 1386 pro-glutathione pro-glutathione JJ 1387 1398 antioxidant antioxidant NN 1398 1399 , , , 1400 1403 was be VBD 1404 1412 observed observe VBN 1413 1415 to to TO 1416 1418 be be VB 1419 1426 capable capable JJ 1427 1429 of of IN 1430 1440 modulating modulate VBG 1441 1449 NF-kappa NF-kappa NNP 1450 1451 B B NNP 1452 1462 activation activation NN 1462 1463 . . .